Novel nonsteroidal antiinflammatory drugs

Acta Gastro-Enterologica Belgica

Volumn 62, Issue 4, 1999, Pages 421-424

  Boutsen, Y ^a   Esselinckx, W ^a  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

COX 2 inhibitors; Cyclooxygenase isoforms; Gastroprotection; Nonsteroidal antiinflammatory drugs

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; MELOXICAM; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; ISOENZYME; LACTONE; MEMBRANE PROTEIN; PEROXIDASE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS1 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; SULFONAMIDE; SULFONE; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; BLEEDING; CLINICAL RESEARCH; CONFERENCE PAPER; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; GASTROINTESTINAL SYMPTOM; GOUT; HUMAN; NEPHROTOXICITY; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; SYNOVITIS; CLINICAL TRIAL; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; LACTONES; MEMBRANE PROTEINS; PEROXIDASES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES; SULFONES; THIAZINES; THIAZOLES;

EID: 0033233428     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. 2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem., 1990, 265: 16737-16740.
2. MASFERRER J.L., ZWEIFEL B.S., MANNING P.T., HAUSER S.D., LEAHY K.M., SMITH W.G. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. USA, 1994, 91 : 3228-3232.
3. LIPSKY P.E., ABRAMSON S.B., CROFFORD L., DUBOIS R.N., SIMON L.S., VAN DE PUTTE L.B. The classification of cyclooxygenase inhibitors. J. Rheumatol., 1998, 25 : 2298-2303.
4. PAIRET M., VAN RYN J., MAUZ A., SCHIEROK H., DIEDEREN W., TÜRCK D., ENGELHARDT G. Differential inhibition of COX-1 and COX-2 by NSAIDs : a summary of results obtained using various test systems. In : Vane J, Botting J, eds. Selective COX-2 inhibitors : pharmacology, clinical effects and therapeutic potential. Dordrecht : Kluwer Academic Publishers, 1998, 3 : 27-46.
5. GARCIA RODRIGUEZ L.A., JICK H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet, 1994, 343 : 769-772..
6. LANGMAN M.J.S., WEIL J., WAINWRIGHT P. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet, 1994, 343 : 1075-1078.
7. HENRY D., LIM L.L.-Y., GARCIA RODRIGUEZ L.A. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs : results of a collaborative meta-analysis. Br. Med. J., 1996, 312: 1563-1566.
8. MITCHELL J.A., AKARASEREENONT P., THIEMERMANN C., FLOWER R.J., VANE J.R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA, 1993, 90 : 11693-11697.
9. DE BRUM-FERNANDES A.J. New perspectives for nonsteroidal antiinflammatory therapy. J. Rheumatol., 1997, 24 : 246-248.
10. PATRONO C. Aspirin as an antiplatelet drug. N. Engl. J. Med., 1994, 330 : 1237-1294.
11. VANE J.R. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature, 1971, 231 : 232-235.
12. PATOIA I., SANTUCCI I., FURNO P. A four-week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptoms evaluation in healthy volunteers. Br. J. Rheumatol., 1996, 35 : 61-67.
13. HAWKEY C., KAHAN A., STEINBRÜCK K., ALEGRE C., BAUMELOU E., BÉGAUD B., DEQUEKER J. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients : the meloxicam large scale international study safety assessment (MELISSA). Br. J. Rheumatol., 1998, 37 : 937-945.
14. DEQUEKER J., HAWKEY C, KAHAN A., STEINBRÜCK K., ALEGRE C., BAUMELOU E., BÉGAUD B. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam : results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. Br. J. Rheumatol., 1998, 37 : 946-951.
15. HAWKEY C.J. COX-2 inhibitors. Lancet, 1999, 353 : 307-314.
16. SIMON L.S., LANZA F.L., LISPKY P.E., HUBBARD R.C., TALWALKER S., SCHWARTZ B.D., ISAKSON P.C., GEIS U.S. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Arthritis & Rheumatism. 1998, 41 (9) : 1591-1602.
17. SCHMEDTJE J.F., JI Y.S., LIU W.L., DUBOIS R.N., RUNGE M.J. Hypoxia induces cyclooxygenase-2 via the NF-KappaB pbs transcription facts in human vascular endothelial cells. J. Biol. Chem., 1997, 272 : 601-608.
18. SIEGLE I., KLEIN T., BACKMAN J.T., SAAL J.G., NÜSING R.M., FRITZ P. Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue. Arthritis & Rheumatism, 1998, 41 (1) : 122-129.
19. INIGUEZ M.A., PABLOS J.L., CARREIRA P.E., CABRÉ F., GOMEZREINO J.J. Detection of COX-1 and COX-2 isoforms in synovial fluid cells from inflammatory joint diseases. Br. J. Rheumatol., 1998, 37: 773-778.